Last reviewed · How we verify
MYOBLOC
MYOBLOC is a botulinum toxin type B that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins.
MYOBLOC is a botulinum toxin type B that blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins. Used for Cervical dystonia (spasmodic torticollis), Blepharospasm, Hemifacial spasm.
At a glance
| Generic name | MYOBLOC |
|---|---|
| Also known as | rimabotulinumtoxinB, botulinum toxin type B, rimabotulinumtoxinB, botulinum toxin type B, Botulinum Toxin Type B |
| Sponsor | Supernus Pharmaceuticals, Inc. |
| Drug class | Botulinum toxin type B |
| Target | VAMP/synaptobrevin (SNARE protein) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
MYOBLOC (rimabotulinumtoxinB) is a botulinum neurotoxin that irreversibly cleaves VAMP/synaptobrevin, a protein essential for acetylcholine vesicle release at the neuromuscular junction. This results in temporary paralysis of muscles at the injection site. Unlike botulinum toxin type A, type B has a different SNARE protein target and may have a faster onset and shorter duration of action in some patients.
Approved indications
- Cervical dystonia (torticollis)
- Blepharospasm
- Strabismus
Common side effects
- Neck pain
- Headache
- Injection site pain
- Muscle weakness
- Dysphagia
- Dry mouth
Key clinical trials
- Efficacy and Safety Study of MYOBLOC in the Treatment of Sialorrhea in Pediatric Subjects (PHASE3)
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity (PHASE2, PHASE3)
- Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity (PHASE2, PHASE3)
- Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects (PHASE3)
- Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults (PHASE3)
- Effect and Safety of Local Injection of Botulinum Toxin Type B Against Digital Ulcer in Systemic Sclerosis (PHASE2)
- Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition and Safety in Patients With Cervical Dystonia
- An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MYOBLOC CI brief — competitive landscape report
- MYOBLOC updates RSS · CI watch RSS
- Supernus Pharmaceuticals, Inc. portfolio CI